0.9098

10.04% 0.083

Citius Oncology Inc (CTOR)

Overview News Price History Discussions Forecast

Citius Oncology Inc stock is traded at $0.9098, with a volume of 231.22K. It is up +10.04% in the last 24 hours and up +39.97% over the past month. Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.

Previous Close:

$0.8268

Open:

$0.8268

24h Volume:

231.22K

Relative Volume:

3.08

Market Cap:

$84.59M

Revenue:

$5.61M

Net Income/Loss:

$-42.51M

P/E Ratio:

-1.9524

EPS:

-0.466

Net Cash Flow:

$-16.86M

1W Performance:

+20.82%

1M Performance:

+39.97%

6M Performance:

-25.43%

1Y Performance:

-47.10%

1-Day Range:

$0.8009

$0.935

1-Week Range:

$0.7064

$0.935

52-Week Range:

$0.4912

$2.25

Citius Oncology Inc Stock (CTOR) Company Profile

Name

Citius Oncology Inc

Sector

Healthcare (1080)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(908) 967-6677

Address

11 COMMERCE DRIVE, CRANFORD

Employee

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

CTOR's Discussions on Twitter

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTOR Citius Oncology Inc	0.9098	75.45M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy
Nov-27-24	Initiated	Maxim Group	Buy

Citius Oncology Inc Stock (CTOR) Latest News

Aug 14, 2026

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Aug 14, 2026

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Aug 14, 2026

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Aug 14, 2026

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Aug 14, 2026

Citius Oncology Q3 Results: Sales miss estimate by 40%, EPS inline - scanx.trade

Aug 14, 2026

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

Aug 14, 2026

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Aug 14, 2026

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Aug 14, 2026

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Aug 13, 2026

Aug 12, 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Aug 12, 2026

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - tradersunion.com

Aug 12, 2026

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada

Aug 12, 2026

Citius Oncology adds independent director to expanded board - TipRanks

Aug 12, 2026

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Nigeria

Aug 12, 2026

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Aug 12, 2026